Logo image of RXST

RXSIGHT INC (RXST) Stock Fundamental Analysis

USA - NASDAQ:RXST - US78349D1072 - Common Stock

8.24 USD
-0.24 (-2.83%)
Last: 10/17/2025, 8:00:02 PM
8.24 USD
0 (0%)
After Hours: 10/17/2025, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RXST. RXST was compared to 191 industry peers in the Health Care Equipment & Supplies industry. While RXST seems to be doing ok healthwise, there are quite some concerns on its profitability. RXST is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year RXST has reported negative net income.
In the past year RXST has reported a negative cash flow from operations.
RXST had negative earnings in 4 of the past 5 years.
In the past 5 years RXST always reported negative operating cash flow.
RXST Yearly Net Income VS EBIT VS OCF VS FCFRXST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -10.44%, RXST is in line with its industry, outperforming 59.16% of the companies in the same industry.
Looking at the Return On Equity, with a value of -11.60%, RXST is in the better half of the industry, outperforming 65.97% of the companies in the same industry.
Industry RankSector Rank
ROA -10.44%
ROE -11.6%
ROIC N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
RXST Yearly ROA, ROE, ROICRXST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

RXST's Gross Margin of 73.12% is amongst the best of the industry. RXST outperforms 84.82% of its industry peers.
In the last couple of years the Gross Margin of RXST has grown nicely.
The Profit Margin and Operating Margin are not available for RXST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
RXST Yearly Profit, Operating, Gross MarginsRXST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

More info and screens

6

2. Health

2.1 Basic Checks

RXST does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RXST has been increased compared to 1 year ago.
The number of shares outstanding for RXST has been increased compared to 5 years ago.
Compared to 1 year ago, RXST has an improved debt to assets ratio.
RXST Yearly Shares OutstandingRXST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RXST Yearly Total Debt VS Total AssetsRXST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 4.85 indicates that RXST is not in any danger for bankruptcy at the moment.
The Altman-Z score of RXST (4.85) is better than 79.58% of its industry peers.
RXST has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
RXST has a better Debt to Equity ratio (0.00) than 75.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.85
ROIC/WACCN/A
WACC8.66%
RXST Yearly LT Debt VS Equity VS FCFRXST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

RXST has a Current Ratio of 13.93. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
RXST has a Current ratio of 13.93. This is amongst the best in the industry. RXST outperforms 97.91% of its industry peers.
RXST has a Quick Ratio of 12.70. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 12.70, RXST belongs to the top of the industry, outperforming 97.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.93
Quick Ratio 12.7
RXST Yearly Current Assets VS Current LiabilitesRXST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

RXST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.37%, which is quite good.
The Revenue has grown by 27.68% in the past year. This is a very strong growth!
RXST shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 128.63% yearly.
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-81.25%
Revenue 1Y (TTM)27.68%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%-3.58%

3.2 Future

The Earnings Per Share is expected to grow by 6.61% on average over the next years.
RXST is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.50% yearly.
EPS Next Y-74.25%
EPS Next 2Y-28.33%
EPS Next 3Y-14.72%
EPS Next 5Y6.61%
Revenue Next Year-10.36%
Revenue Next 2Y-2.2%
Revenue Next 3Y2.02%
Revenue Next 5Y2.5%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
RXST Yearly Revenue VS EstimatesRXST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
RXST Yearly EPS VS EstimatesRXST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RXST. In the last year negative earnings were reported.
Also next year RXST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXST Price Earnings VS Forward Price EarningsRXST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXST Per share dataRXST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as RXST's earnings are expected to decrease with -14.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.33%
EPS Next 3Y-14.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RXST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RXSIGHT INC

NASDAQ:RXST (10/17/2025, 8:00:02 PM)

After market: 8.24 0 (0%)

8.24

-0.24 (-2.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners96.45%
Inst Owner Change0.18%
Ins Owners5.56%
Ins Owner Change10.61%
Market Cap337.18M
Analysts52.5
Price Target9.18 (11.41%)
Short Float %12.45%
Short Ratio4.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.73%
Min EPS beat(2)-16.68%
Max EPS beat(2)9.22%
EPS beat(4)3
Avg EPS beat(4)9.97%
Min EPS beat(4)-16.68%
Max EPS beat(4)36.3%
EPS beat(8)7
Avg EPS beat(8)17.13%
EPS beat(12)11
Avg EPS beat(12)18.4%
EPS beat(16)14
Avg EPS beat(16)15.43%
Revenue beat(2)0
Avg Revenue beat(2)-4.41%
Min Revenue beat(2)-6.3%
Max Revenue beat(2)-2.53%
Revenue beat(4)0
Avg Revenue beat(4)-3.07%
Min Revenue beat(4)-6.3%
Max Revenue beat(4)-1.26%
Revenue beat(8)4
Avg Revenue beat(8)0.64%
Revenue beat(12)8
Avg Revenue beat(12)2.65%
Revenue beat(16)12
Avg Revenue beat(16)4.55%
PT rev (1m)0%
PT rev (3m)-58.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-45.62%
EPS NY rev (1m)0%
EPS NY rev (3m)-38.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-33.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-22.09%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.29
P/FCF N/A
P/OCF N/A
P/B 1.21
P/tB 1.21
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS3.59
BVpS6.79
TBVpS6.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.44%
ROE -11.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.12%
FCFM N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 125.95%
Cap/Sales 2.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.93
Quick Ratio 12.7
Altman-Z 4.85
F-Score5
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)107.67%
Cap/Depr(5y)87%
Cap/Sales(3y)4.72%
Cap/Sales(5y)8.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-81.25%
EPS Next Y-74.25%
EPS Next 2Y-28.33%
EPS Next 3Y-14.72%
EPS Next 5Y6.61%
Revenue 1Y (TTM)27.68%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%-3.58%
Revenue Next Year-10.36%
Revenue Next 2Y-2.2%
Revenue Next 3Y2.02%
Revenue Next 5Y2.5%
EBIT growth 1Y-0.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.97%
EBIT Next 3Y5.73%
EBIT Next 5YN/A
FCF growth 1Y63.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.06%
OCF growth 3YN/A
OCF growth 5YN/A